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    Abstract 
    A simple, rapid and validated high performance liquid chromatography 
method with UV detection for the quantification of an opioid agonist, fentanyl 
(FEN), in rat plasma was developed. The assay procedure involved 
chromatographic separation using a ZIC-HILIC SeQUANT column (250 × 4.6 
mm, i.d., 5 µm) and a mobile phase of acetonitrile and acetate buffer (pH 3.4, 20 
mM) of ratio (= 65:35, v/v) at a flow rate of 1.2 mL/min and detection 
wavelength of 201 nm. Plasma sample (100 μL) pretreatment was based on 
simple deprotienization by acetonitrile spiked with clonidine as an internal 
standard (I.S.) of 20 ng/mL followed by extraction with tert-butyl methyl ether 
and centrifugation. The organic layer was evaporated under N2 gas and 
reconstituted with 100 μL of acetate buffer (pH 3.4, 20 mM), and 50-μL 
portions of reconstituted sample were injected onto the column. Sample analysis 
including sample pretreatment was achieved within 35 min. Calibration curve 
was linear (r ≥ 0.998) from 5 to 100 ng/mL. Both intra- and inter-day assay 
precisions that are presented through R.S.D were lower than 12.6% for intra-day 
and lower than 12.0% for inter-day assessment. Limit of detection was 0.8 
ng/mL at S/N of 3. This method was omitting the use of expensive solid phase 
extraction and time consuming liquid extraction procedures. Moreover, the 
present method was successfully applied to study pharmacokinetic parameters 
of FEN after intraperitoneal administration to male Wistar rat. Pharmacokinetic 
parameters estimated by using moment analysis were; T1/2 198.3 ± 44.7 min, 
Tmax 28.3 ± 2.9 min and AUC0-180 15.6
 ± 2.9 (×102) ng·min/mL.  
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    Fentanyl [N-phenyl-N-(1-(2-phenylethyl)piperidyl)propanamide, FEN] is a 
potent synthetic µ-opioid agonist that is commonly used for anesthesia, 
analgesia for post-operative surgical procedure and chronic pain management 
mainly for cancer patients. FEN in its various dosage forms has been illicitly 
used either alone [1,2,3] or in combination with other drugs including 
antidepressants, opioids, benzodiazepines, and amphetamines [3,4].  
    Due to variation of FEN use, misuse and its high potency; several studies 
have been reported for its detection in biological samples and different body 
organs using various separation and detection techniques including high-
performance liquid chromatography (HPLC) coupled to tandem mass 
spectroscopy [5], and some other HPLC-UV methods [6,7,8]. These methods 
included different types of extraction procedures such as liquid-liquid extraction 
(LLE) utilizing hexane to extract target analytes [6, 7], solid phase extraction 
(SPE) [9] and single-drop liquid-liquid-liquid micro-extraction (LLME) [10]. 
All these reported methods were developed with attention to sensitivity, method 
applicability and reproducibility. 
    This work was conducted to develop and validate a method that is convenient, 
simple and rapid for FEN determination in rat plasma, coupled to 
pharmacokinetic study after single intraperitoneal (i.p.) administration of FEN 
0.1 mg/kg to male Wistar rat. 
    This method is characterized by the usage of 100 µL of plasma, and the 
simplicity of not using any derivatization reaction or pre-extraction procedure. 







2.1. Reagents and standards 
    FEN citrate stock (from Daiichi Sankyo Co. Ltd, Tokyo) was kindly gifted by 
the National Institute of Health Sciences, Ministry of Health and Welfare 
(Japan). Clonidine·HCl was used as the internal standard (I.S.) of 20 ng/mL. 
Sodium carbonate, sodium hydrogen carbonate, sodium acetate, acetonitrile 
were obtained from Wako Pure Chemicals (Osaka, Japan). Acetic acid was 
obtained from Nacalai Tesque, Inc. (Kyoto, Japan). tert-Butyl methyl ether (t-
BME) was obtained from Sigma-Aldrich, Inc. (MO, USA). Water for buffers 
was passed through a pure line WL21P (Yamato Science, Tokyo). Nitrogen gas 
of 99.999% purity was provided by Daiichisanso (Nagasaki, Japan). 
    Stock solutions (50 μg/mL) of FEN and I.S. were subsequently diluted to 
prepare working standards with acetonitrile. Standards of calibration curves 
were prepared by pipetting suitable amounts of FEN and I.S. (20 ng/mL) and 
spiking them into rat plasma, and all stock solutions were kept at 4 oC. 
2.2. Chromatographic apparatus and conditions 
    The HPLC system consisted of a Shimadzu LC-10ATvp liquid 
chromatographic pump (Shimadzu, Kyoto, Japan), a ZIC-HILIC SeQUANT 
column (250 × 4.6 mm i.d.; 5 μm, Merck, Darmstadt, Germany), a Shimadzu 
SPD-10A utilized as a detector at a wavelength of 201 nm and a 7125 injector 
with 50-μL sample loop (Rheodyne, CA, USA). The mobile phase was a 
mixture of acetonitrile and sodium acetate buffer (pH 3.4, 20 mM) with a ratio 
of (=65:35, v/v). The mobile phase was degassed and pumbed into the column at 
a flow rate of 1.2 mL/min. 
2.3. Plasma collection 
    Male Wistar rat's plasma was used in the experiments (Kyudo Experimental 
Animal, Saga, Japan). The rats were housed in the conditions of constant 
temperature (24 ± 1oC), provided with standard laboratory food (Oriental Yeast, 
Tokyo) and water ad libitium. All animal procedures and care in this experiment 
were permitted by Nagasaki University Animal Care Use Committee. The rats 
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were anesthetized with ethyl carbamate (1.5 g/kg, i.p.). After operating on rats 
and inserting the cannula into the femoral artery, rats were stabilized for one 
hour and then blood samples were collected into EDTA containing eppendorf 
tubes.  Samples were centrifuged at 2000g for 10 min at 20oC, the obtained 
plasma samples were kept at -30oC prior to use. 
2.4. Plasma pretreatment 
    To 100 μL of rat plasma 10 μL of I.S. (final concentration is 20 ng/mL in 
plasma) was spiked and vortex-mixed for 20 sec. To this solution, 40 μL of 
sodium carbonate buffer (pH 11.2, 100 mM) were added and vortex-mixed for 1 
min. Followed by the addition of 500 μL t-BME, which was vortex-mixed for 1 
min and then centrifuged at 2000g for 20 min at 10 oC, 400 μL organic layer was 
transferred into a test tube. Collected organic layer extract was evaporated to 
dryness under N2 gas, the residue was reconstituted with 100 μL sodium acetate 
buffer (pH 3.4, 20 mM), and 50 μL of reconstituted volume were injected onto 
the column.  
2.5. Validation of the method 
    Calibration curves were prepared using plasma samples spiked with known 
concentrations of FEN (final concentrations in plasma were 10, 20, 50, 100 
ng/mL); triplicate for each concentration was used. The limits of detection 
(LOD) and quantitation (LOQ) were calculated as the peak height at a signal-to-
noise (S/N) ratio of 3 and 10, respectively. Intra- and inter-day assay precision, 
accuracy and recovery were assessed using rat plasma spiked with 10, 50 and 
100 ng/mL of FEN and 20 ng/mL of I.S were used, five replicate measurements 
for each standard concentration were performed. The accuracy was calculated as 
found concentration/nominal concentration, while the recovery was calculated 
as peak height ratio of FEN to I.S. in plasma/peak height ratio of standard FEN 
to standard I.S. 
2.6. Application to pharmacokinetic study on rat 
    An in vivo pharmacokinetic study was performed in male Wistar rat (n=3, 
weight 295-320 and 7-8 weeks old). Blood sampling after administration of 
FEN (0.1 mg/kg, i.p.) was held at 0, 10, 15, 20, 25, 30, 40, 90, 120 and 180 min, 
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the used dose of FEN is consistent with previously reported method for rat 
treatment [11,12]. Blood was collected as previously explained, followed by 
spiking of 10 μL  I.S. solution to each plasma sample, and pretreated as 
mentioned earlier. The concentrations of FEN in rat plasma were calculated 
from the corresponding calibration curve. The peak concentration (Cmax) and 
concentration peak time (Tmax) were obtained directly from the original data. 
The elimination half-life (T1/2) was calculated using the equation 0.693/k (k= 
rate constant), also clearance (CL) was calculated as the dose/area under the 
curve for concentration versus (vs.) time (AUC0-180). Other parameters such as 
AUC0-180, and the mean residence time (MRT0-180) were calculated by 




3. Results and discussion  
   This HPLC-UV method for FEN determination in rat plasma represents 
considerably simple and rapid bioanalytical technique. Moreover, among many 
of analytical techniques, HPLC-UV is the most abundant technique and the least 
costly, especially when combined to simple liquid extraction unlike SPE [9]. 
Portier et al. [7] reported a method utilizing simple LLE, using 1 mL of human 
plasma and an injection volume of 100 μL, while this method is using a small 
plasma volume that equals to 100 μL and injection volume of 50 μL. LLME that 
was reported previously is requiring pre-extraction and back-extraction method 
combined to the tedious micro-droplet acceptor phase, and takes 50 min for 
extraction procedure only [10], whereas this method using simple liquid 
extraction makes it the handiest method to perform, that takes 35 min to obtain 
the final peak on the chromatogram. With these qualities, this method can be 
used for FEN pharmacokinetic assessment in rats, FEN drug interactions studies 
and will give possible use for forensic purposes after slight modifications. 
3.1. Chromatography  
    During the development of the method, various mobile phases were assessed. 
Eventually, the ratio of acetonitrile and sodium acetate buffer (pH 3.4, 20 mM) 
(=35:65, v/v) provided the optimal separation of FEN and I.S. with retention 
times of 6.6 and 8.0 min, respectively. Figure 1 represents typical 
chromatograms obtained from (A) plasma free drug and (B) that is spiked with 
FEN 50 ng/mL and I.S. 20 ng/mL. There were no interferences from the blank 
plasma. Also for FEN treated rats, no interfering peaks were detected. The 
implementation of 201 nm as detection wavelength was considered after 
practically achieving better sensitivity. Additionally, the UV spectrum of FEN 
in mobile phase showed two maximum absorption peaks at 210 nm and 258 nm, 
these results are consistent with the previously reported methods that are using 
detection wavelengths ranging from 200-210 nm [6,7,8]. 
    Upon the usage of a ZIC-HILIC column with its unique zwitterionic 
functional group, a clear relationship between the ionization capacities of FEN 
and examined internal standards to their corresponding retention times was 
established. Additionally, the column ability to retain FEN and I.S. for short 
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time made it favourable to utilize for this method. The usage of t-BME 
overcame the presence of early peaks that were appearing when hexane or 
dichloromethane was examined; this helped us to obtain a clear chromatogram 
as shown in Fig.1.  
Figure 1 
3.2. Stability of FEN in blood sample 
    The stability of FEN at -30 oC was examined using rat plasma containing 20 
ng/mL of FEN; four cycles of freeze-thaw were utilized. Furthermore, the 
stability of FEN for a long period freezing was studied over a period of three 
months. The results showed FEN concentrations for freeze-thaw and freezing 
cycles were 18.5 ± 1.6 and 17.8 ± 1.5 ng/mL (mean ± SD, n=3), respectively.  
3.3. Method Validation  
    The calibration curve in rat plasma spiked with FEN and I.S. was obtained by 
plotting the peak height ratio of FEN to I.S. of 20 ng/mL vs. the concentration in 
ng/mL, with a replicate of three times. The calibration curve was linear in the 
range of 5-100 ng/mL with a correlation coefficient of (r = 0.998). LOD and 
LOQ at S/N ratio of 3 and 10 were 0.8 and 3.0 ng/mL, respectively. Parameters 
of calibration curve for the proposed method are summarized in Table 1. 
Table 1 
    Intra-day and inter-day precisions of the proposed method were evaluated by 
analyzing five replicates of plasma samples spiked with known concentrations 
of FEN (10, 50 and 100 ng/mL) and I.S (20 ng/mL). The intra-day assay 
precision (relative standard deviation, RSDs) were 12.0 (10 ng/mL), 6.3 (50 
ng/mL) and 3.9% (100 ng/mL). Inter-day assay precision (RSDs) were 12.6% 
(10 ng/mL), 7.3% (50 ng/mL) and 2.3% (100 ng/mL). The accuracies were 
ranging from 92 to 101%, and recoveries ranging from 92 to 96% (Table 2). The 
guidelines for the international conference of harmonization (ICH) were utilized 




3.4. Pharmacokinetics of FEN in rats  
    The proposed method was applied on male Wistar rats to investigate 
pharmacokinetic behaviour after i.p. administration of FEN. Several sampling 
schedules were assessed till we achieved the most appropriate duration of 
detection. A dose of 0.1 mg/kg was used for treatment though it represented 
relatively higher plasma concentration than that of therapeutic in human, but 
same time it satisfied the proposed goal of pharmacokinetic determination. The 
obtained pharmacokinetic parameters are summarized in Table 3. 
Table 3 
    The concentration of FEN in rat plasma was monitored after i.p. 
administration (Fig.2). Time to achieve maximum concentration in plasma was 
28.3 ± 2.9 min (Tmax), the maximum peak concentration (Cmax) was 21.3 ± 4.9 
ng/mL, the elimination half-life (T1/2) was 198.3 ± 44.7 min, area under the 
curve for concentration vs. time (AUC0-180) was 15.6 ± 2.9 × 10
2 ng·min/mL, 
the mean residence time (MRT0-180) was 75.3 ± 8.7 min and CL was 19.4 ± 2.6 
mL/min.  
Figure 2 
    The amount of data discussing FEN pharmacokinetics after i.p. administration 
is few. An IV administration of 200 μg FEN was conducted on humans, this 
study reported the pharmacokinetic parameters as follows; (Cmax) of 1.46 ± 0.66 
ng/mL, median (Tmax) of 0.17 hours and (T1/2) of 18.03 ± 10.08 hours [14]. This 
data shows a widely different change compared to rat, which can be ascribed to 
many factors; first: the different rout of administration and small blood volume 
of rat compared to human, second: amount of fatty tissue that enhance the 
distribution of FEN as it is considered to be highly lipophilic drug. Other 
reported methods for FEN determination are using animals that are difficult to 
handle and operate, these methods are assessing the pharmacokinetic parameters 
after subcutaneous administration of FEN in Greyhounds and horses [15,16]. 
None of the method reported studied FEN determination in male Wistar rats. 





     As FEN has many effects over human health, it has been studied with great 
emphasis in order to maximize its effectiveness and reduce the amount of side 
effects related to this potent opioid. Therefore, the availability of a method that 
can improve the understanding of FEN interaction with other drugs would 
definitely be of a great advantage. The currently available methods using the 
simple method of HPLC-UV are either consuming a large volume of plasma 
sample or has multiple augmentation of concentrations while reconstitution 
which render them tedious and improbable to handle easily. On the other hand, 
the highly sensitive methods of LC-MS are of restricted accessibility to research 
laboratories. Our HPLC-UV detection method is considerably simple, time 
saving, reproducible and relatively sensitive. This method is suitable for 
complete pharmacokinetic analysis in small animals with possible utilization in 
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y = (0.02 ± 0.001)x + 
(0.043 ± 0.007) 
0.8 3.0 
1 Correlation coefficient. 
2 y= peak height ratio of FEN to I.S.; x= Sample concentration, ng/mL. 
3 Slope and y-intercept were expressed as mean ± SD (n=3). 














































     
     Recovery % 
 
 Accuracy %2  
Intra-day Inter-day 
10 12.0 12.6 96 93 
50 6.3 7.3 92 92 
100 3.9 2.3 95 101 
1 Relative standard deviation. 




































Pharmacokinetic parameters of FEN after single administration of 0.1 mg/kg 
intraperitoneally* 
  
Parameter Mean ± SD (n = 3) 
Tmax, min 28.3 ± 2.9 
Cmax, min 21.3 ± 4.9 
T1/2, min 198.3 ± 44.7 
AUC0-180, ng·min/mL 15.6 × 10
2 ± 2.9 × 102 
MRT0-180, min 75.3 ± 8.7 
CL, mL/min 19.4 ± 2.6 
 * Moment analysis was used to determine pharmacokinetic parameters. 
 
 



















Fig.1. Chromatograms of (A) plasma and (B) spiked plasma with FEN (50 





Fig.2. Concentration-time profile of FEN in rat plasma after single 
administration of FEN (0.1 mg/kg). 
